دورية أكاديمية
أعرض في EDS

The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cell homing to bone.

التفاصيل البيبلوغرافية
العنوان: The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cell homing to bone.
المؤلفون: Pal S; Division of Endocrinology, Metabolism and Lipids, Department of Medicine, and.; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA., Perrien DS; Division of Endocrinology, Metabolism and Lipids, Department of Medicine, and.; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA., Yumoto T; Department of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, Georgia, USA., Faccio R; Department of Orthopedics, Washington University in St. Louis, St. Louis, Missouri, USA., Stoica A; Division of Endocrinology, Metabolism and Lipids, Department of Medicine, and.; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA., Adams J; Division of Endocrinology, Metabolism and Lipids, Department of Medicine, and.; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA., Coopersmith CM; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA.; Department of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, Georgia, USA., Jones RM; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA.; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Emory University, Atlanta, Georgia, USA., Weitzmann MN; Division of Endocrinology, Metabolism and Lipids, Department of Medicine, and.; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA.; Atlanta VA Health Care System, Department of Veterans Affairs, Decatur, Georgia, USA., Pacifici R; Division of Endocrinology, Metabolism and Lipids, Department of Medicine, and.; Emory Microbiome Research Center, Emory University, Atlanta, Georgia, USA.; Immunology and Molecular Pathogenesis Program, Emory University, Atlanta, Georgia, USA.
المصدر: The Journal of clinical investigation [J Clin Invest] 2022 Jun 15; Vol. 132 (12).
نوع المنشور: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: Gastrointestinal Microbiome* , Melanoma, Experimental*/pathology , Osteolysis*, Animals ; Anti-Bacterial Agents/pharmacology ; Bone Development ; Humans ; Mice ; Mice, Inbred C57BL ; Quality of Life ; Th1 Cells/pathology
مستخلص: Bone metastases are frequent complications of malignant melanoma leading to reduced quality of life and significant morbidity. Regulation of immune cells by the gut microbiome influences cancer progression, but the role of the microbiome in tumor growth in bone is unknown. Using intracardiac or intratibial injections of B16-F10 melanoma cells into mice, we showed that gut microbiome depletion by broad-spectrum antibiotics accelerated intraosseous tumor growth and osteolysis. Microbiome depletion blunted melanoma-induced expansion of intestinal NK cells and Th1 cells and their migration from the gut to tumor-bearing bones. Demonstrating the functional relevance of immune cell trafficking from the gut to the bone marrow (BM) in bone metastasis, blockade of S1P-mediated intestinal egress of NK and Th1 cells, or inhibition of their CXCR3/CXCL9-mediated influx into the BM, prevented the expansion of BM NK and Th1 cells and accelerated tumor growth and osteolysis. Using a mouse model, this study revealed mechanisms of microbiota-mediated gut-bone crosstalk that are relevant to the immunological restraint of melanoma metastasis and tumor growth in bone. Microbiome modifications induced by antibiotics might have negative clinical consequences in patients with melanoma.
التعليقات: Comment in: Nat Rev Cancer. 2022 Sep;22(9):494-495. (PMID: 35941222)
References: Nat Commun. 2020 Jan 24;11(1):468. (PMID: 31980603)
PLoS One. 2013 Nov 06;8(11):e79939. (PMID: 24223204)
Biomed Res Int. 2014;2014:413982. (PMID: 25197644)
J Vis Exp. 2012 Sep 04;(67):e4260. (PMID: 22972196)
For Immunopathol Dis Therap. 2016;7(1-2):41-55. (PMID: 28616355)
Proc Natl Acad Sci U S A. 2014 May 6;111(18):6696-701. (PMID: 24753589)
J Exp Med. 1981 Mar 1;153(3):569-82. (PMID: 6166701)
J Immunol. 1993 Sep 1;151(5):2511-20. (PMID: 8103068)
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61. (PMID: 9636188)
Cell Mol Immunol. 2020 Jan;17(1):1-12. (PMID: 31611651)
PeerJ. 2017 Jun 15;5:e3450. (PMID: 28630804)
Comput Methods Biomech Biomed Engin. 1997;1(1):15-23. (PMID: 11264794)
Cell Metab. 2015 Nov 3;22(5):799-810. (PMID: 26456334)
Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101. (PMID: 20061941)
J Immunol. 2001 Feb 15;166(4):2276-82. (PMID: 11160282)
ACS Med Chem Lett. 2013 Jan 04;4(3):333-7. (PMID: 24900670)
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10. (PMID: 14612570)
J Bone Miner Res. 2014 Jan;29(1):43-54. (PMID: 24357520)
J Invest Dermatol. 2006 Jan;126(1):32-41. (PMID: 16417215)
Cancer Res. 2008 Oct 15;68(20):8437-45. (PMID: 18922917)
J Bone Miner Res. 2018 Dec;33(12):2099-2113. (PMID: 30476357)
Immunol Rev. 1997 Jun;157:177-94. (PMID: 9255630)
Trends Immunol. 2015 Jan;36(1):49-58. (PMID: 25432489)
J Bone Miner Res. 2016 Sep;31(9):1638-46. (PMID: 27317164)
Cancer Res. 2003 Aug 15;63(16):4763-5. (PMID: 12941790)
Nat Rev Microbiol. 2013 Apr;11(4):227-38. (PMID: 23435359)
Nature. 2012 Nov 8;491(7423):254-8. (PMID: 23034650)
Int Immunopharmacol. 2018 Oct;63:66-73. (PMID: 30075430)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Apoptosis. 2003 Jun;8(3):237-49. (PMID: 12766484)
J Bone Miner Res. 2017 Jun;32(6):1343-1353. (PMID: 28244143)
Trends Immunol. 2015 Dec;36(12):778-787. (PMID: 26596799)
Cell. 2021 Oct 14;184(21):5338-5356.e21. (PMID: 34624222)
J Pathol. 2008 Jan;214(2):179-89. (PMID: 18161751)
Clin Cancer Res. 2002 Mar;8(3):922-31. (PMID: 11895927)
Exp Ther Med. 2019 Dec;18(6):4845-4851. (PMID: 31772648)
J Clin Invest. 2020 Apr 1;130(4):1767-1781. (PMID: 31917685)
J Bone Miner Res. 1999 Jul;14(7):1167-74. (PMID: 10404017)
Cancer Res. 2019 Dec 1;79(23):5999-6009. (PMID: 31591154)
Exp Cell Res. 2011 Mar 10;317(5):620-31. (PMID: 21376175)
Immunity. 2019 Jun 18;50(6):1498-1512.e5. (PMID: 31097342)
Science. 1977 Aug 26;197(4306):893-5. (PMID: 887927)
Gut Microbes. 2020 Jul 3;11(4):1030-1042. (PMID: 32240032)
Br J Pharmacol. 2012 Nov;167(5):1035-47. (PMID: 22646698)
Nat Rev Cancer. 2002 Nov;2(11):850-61. (PMID: 12415255)
Eur J Immunol. 2006 Sep;36(9):2394-400. (PMID: 16917961)
J Bone Miner Res. 2020 Apr;35(4):801-820. (PMID: 31886921)
J Clin Invest. 2021 Feb 15;131(4):. (PMID: 33586672)
Cell. 2004 Jul 23;118(2):229-41. (PMID: 15260992)
J Oncol. 2012;2012:647684. (PMID: 22792102)
Neural Regen Res. 2019 Nov;14(11):1950-1960. (PMID: 31290453)
J Bone Miner Res. 2010 Jul;25(7):1468-86. (PMID: 20533309)
Bone. 2018 Oct;115:59-67. (PMID: 28433758)
Bone. 2007 Oct;41(4):505-15. (PMID: 17693147)
J Clin Invest. 2010 Mar;120(3):883-93. (PMID: 20179354)
Cell. 2017 Jul 27;170(3):548-563.e16. (PMID: 28753429)
Int J Mol Sci. 2021 Jul 27;22(15):. (PMID: 34360802)
Science. 1996 May 3;272(5262):719-22. (PMID: 8614832)
Nat Med. 2016 May;22(5):516-23. (PMID: 27019327)
iScience. 2021 Aug 20;24(9):103012. (PMID: 34522855)
Nat Immunol. 2007 Dec;8(12):1337-44. (PMID: 17965716)
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10871-6. (PMID: 18663225)
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365. (PMID: 28270698)
J Biomed Biotechnol. 2011;2011:473097. (PMID: 21660136)
J Invest Dermatol. 2005 Jul;125(1):159-165. (PMID: 15982316)
J Bone Miner Res. 2015 Apr;30(4):695-705. (PMID: 25359628)
Cancer J. 2015 Jul-Aug;21(4):343-50. (PMID: 26222088)
J Leukoc Biol. 2016 Nov;100(5):865-879. (PMID: 27605211)
Immunity. 2016 Nov 15;45(5):1078-1092. (PMID: 27851911)
Immunol Rev. 2007 Dec;220:169-82. (PMID: 17979846)
Cancer Immunol Immunother. 2015 Feb;64(2):225-35. (PMID: 25344904)
Elife. 2021 Jan 12;10:. (PMID: 33432923)
Oncoimmunology. 2016 Sep 20;5(12):e1235106. (PMID: 28151533)
Cancer Res. 2019 Jul 15;79(14):3662-3675. (PMID: 31064848)
Transplant Proc. 2001 Feb-Mar;33(1-2):530-1. (PMID: 11266942)
J Immunol. 2000 Nov 15;165(10):5495-501. (PMID: 11067902)
Int J Med Microbiol. 2010 Jan;300(1):11-8. (PMID: 19781991)
Cell. 2014 May 8;157(4):776-83. (PMID: 24813605)
Nat Rev Immunol. 2006 Dec;6(12):940-52. (PMID: 17124515)
J Clin Invest. 2016 Jun 1;126(6):2049-63. (PMID: 27111232)
Science. 2013 Nov 22;342(6161):967-70. (PMID: 24264989)
معلومات مُعتمدة: R01 DK112946 United States DK NIDDK NIH HHS; S10 RR028009 United States RR NCRR NIH HHS; U54 AG062334 United States AG NIA NIH HHS; R01 CA270030 United States CA NCI NIH HHS; R01 GM072808 United States GM NIGMS NIH HHS; R01 AR066551 United States AR NIAMS NIH HHS; R01 GM104323 United States GM NIGMS NIH HHS; R01 DK119229 United States DK NIDDK NIH HHS; R01 DK124821 United States DK NIDDK NIH HHS; T32 GM095442 United States GM NIGMS NIH HHS; R01 AR079298 United States AR NIAMS NIH HHS; R01 AR068157 United States AR NIAMS NIH HHS; R01 AR070091 United States AR NIAMS NIH HHS; I01 BX000105 United States BX BLRD VA; R01 CA235096 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Bone Biology; Melanoma
المشرفين على المادة: 0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20220503 Date Completed: 20220616 Latest Revision: 20231109
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9197523
DOI: 10.1172/JCI157340
PMID: 35503658
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI157340